Neurological disorders news - the latest biotech news

Home Neurological disorders Page 13

Latest Posts

News and Trends 16 Apr 2016

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

We last wrote about GeNeuro in January, when they announced the launch of an IPO for their Multiple Sclerosis phase IIb trial. Now, as of yesterday they are listed on the Euronext Paris market. GeNeuro (in Geneva) is developing therapies and diagnostic tools for diseases associated with the expression of the human endogenous retrovirus MSRV, such […]

April 16, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 11 Apr 2016

It’s World Parkinson’s Disease Day! #EndParkinsons

Today (April 11th) is the birthday of the memorable Dr James Parkinson, who discovered this major neurodegenerative disease. So what is Parkinson’s Disease, and who is researching it? First described in 1817 by James Parkinson, Parkinson’s Disease (PD) is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer’s. Since PD mainly affects […]

April 11, 2016 - 4 minutesmins - By Dani Bancroft

News and Trends 11 Apr 2016

French Biotech gets €34M to bring Multiple Sclerosis Drug to the US

MedDay (France) has raised €34M that should help pay a US phase III for its leading candidate for Multiple Sclerosis – as well as its commercial launch in Europe. Based in Paris, MedDay is a Biotech developing new drugs targeting brain metabolism to treat diseases of the nervous system. Its leading candidate, MD1003, has a mixed track record. […]

April 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 7 Apr 2016

Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech

Heptares Therapeutics is licensing its portfolio of novel candidates for neurological diseases, including one for Alzheimer’s, to Allergan for up to €3Bn. A good way for Allergan to ‘get over’ yesterday’s failed Pfizer acquisition. Based in Cambridge, UK, Heptares Therapeutics is creating new therapies with their StaR platform, that allows it to target G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to many […]

April 7, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 24 Mar 2016

Leading German Biotech recruits New talent for Fight against Alzheimer’s

Probiodrug (Germany) has hired Mark Booth as Chief Business Officer to propel this Pharma’s global strategy. Among other important roles, Booth was president of Takeda North America. Probiodrug is a Biopharma focused on developing treatments for Alzheimer’s disease. Its strategy is based on the elimination of pyroglutamated Abeta (pGlu), which is one of the way Alzheimer’s […]

March 24, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 17 Mar 2016

A Relief for Migraines at last? The Biotech race for the Ultimate Cure

A Migraine is more than just a headache; it is a neurological disorder affecting a staggering 10% of the worldwide population. So where are we on fighting a viable therapy – and who is working on Migraines? People of all ages are at risk of migraine, with women being three times more likely to suffer from […]

March 17, 2016 - 4 minutesmins - By Ekaterina Perets

ADVERTISEMENT

News and Trends 3 Mar 2016

Reviewing Autism: Can Biotech open up New Horizons?

While Autism Spectrum Disorders (ASD) affect approximately one in 68 children, this hasn’t provoked much enthusiasm among pharmaceutical companies to develop drugs. However, recent advances in basic research Autism and novel gene-editing technologies may boost ASD drug development. The reasons for low interest are a poor understanding of the biological mechanisms underlying Autism Spectrum Disorder, the […]

March 3, 2016 - 6 minutesmins - By Ekaterina Perets

News and Trends 11 Feb 2016

Sanofi-Genzyme: Still successful 5 years after the acquisition?

Back in 2011, France’s biggest Pharmaceutical company Sanofi decided to purchase Genzyme Corp. for more than $20 billion, thus becoming the latest global drug giant to acquire a big biotech to foster its R&D pipeline. 5 years later, what’s the situation for Genzyme and Sanofi? So often when a large Pharma acquires a smaller Biotech, […]

February 11, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Feb 2016

Finland, France and Harvard Bioprint Brains to Understand the 3D Structure

Researchers at Harvard University in collaboration with French and Finnish academic institutions have managed to 3D-bioprint a brain with the distinctive folds; An essential adaptation for our cognitive development. Harvard University worked with the CNRS at Aix Marseille Université (France), Institut Mines-Telecom INSERM (France) and the University of Jyväskylä (Finland). The team then published in Nature Physics what they discovered […]

February 4, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 25 Jan 2016

Also Using PD-L1 Cancer Treatments to Attack Alzheimer’s Disease

What updates have occurred in the Neurodegenerative disease field as of late? New appointments by the Dementia Discovery Fund, which widens its international reach – and new ‘out of the box’ ideas from Israel and South Korea. The Dementia Discovery Fund (DDF), an innovative global investment fund managed by SV Life Sciences and launched in October […]

January 25, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 22 Jan 2016

Groningen’s MedTech Hub for Neurosurgery is Actually a Biotech Hotspot

I visited Groningen (Netherlands) and the University Medical centre there in November, and it was interesting to note the tight knit Biotechnology and medical research bubble which has been enlarging, now making multiple outbound research and clinical trial links to the US. One such example is Polyganics, which has signed an exclusive distribution agreement with its US strategic […]

January 22, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Jan 2016

Epigenetics Baby of Proteros is Signing Up with Top US Neurology Specialists

Founded in just 2013 by German Proteros and the US Atlas Ventures, Rodin Therapeutics is working epigenetics into discovery of novel therapies for Neurological diseases. Now they have hooked one of the largest players in the field, Biogen, into a €446M partnership. Since its inception within Atlas Venture’s company-creating seed program in March 2013, Rodin […]

January 8, 2016 - 3 minutesmins - By Dani Bancroft

ADVERTISEMENT